drugset / Trial / NCT02577250

Ketamine Infusions for PTSD and Treatment-Resistant Depression

NCT02577250

Phase 1 Completed 20 enrolled Minneapolis Veterans Affairs Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The relationship between depression and trauma is well established. Co-occuring depression and post-traumatic stress disorder (PTSD) are associated with more severe symptoms and lower levels of functioning. Veterans with both depression and PTSD have been shown to be at much higher risk of suicide than individuals with only one of these disorders. Ketamine has been shown to have rapid antidepressant effects and also therapeutic action over PTSD symptoms. The purpose of this study is to see whether ketamine, when given as repeated infusions, can produce quick and sustained improvement in depression and PTSD symptoms for individuals who have not had their symptoms effectively treated by current treatments.

Timeline

Start
2015-05
Primary completion
2016-06
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous